Clinical Pharmacotherapy Reference Guide
Based on: NCCN Guidelines v1.2026 — Prevention & Treatment of Cancer-Related Infections (March 11, 2026)
NCCN Hematopoietic Growth Factors v3.2026 · IDSA CDI 2021 Focused Update
All NCCN recommendations are Category 2A unless otherwise noted.
DEFINITIONS & KEY CUTOFFS
| Term | NCCN Definition |
|---|---|
| Fever | Single oral temperature ≥38.3°C OR ≥38.0°C sustained over 1 hour |
| Neutropenia | ANC ≤500 cells/mcL OR ≤1000 cells/mcL with predicted decline to ≤500 over the next 48 hours |
| Febrile Neutropenia (FN) | Fever PLUS neutropenia as defined above — oncologic emergency requiring immediate evaluation and empiric antibiotics within 1 hour |
| Profound Neutropenia | ANC <100 cells/mcL — highest risk for bloodstream infections; 10–20% will develop BSI at this level |
| Prolonged Neutropenia | ANC ≤100 cells/mcL for ≥7 days — significant mold infection risk after 4–7 days of persistent fever |
| MDRO | Microorganisms resistant to ≥1 class of antimicrobial agents. MRSA is the prototypical MDRO (NCCN v1.2026 updated definition) |
| Recurrent CDI | Symptom onset + positive assay within 2–8 weeks of prior positive episode |
💎 PEARL: ~50–60% of febrile neutropenic patients have an established or occult infection. Only 20–30% have a microbiologically documented infection.
💎 PEARL: Virtually ALL patients with FN require IV broad-spectrum antibiotics REGARDLESS of risk score — the difference is location (inpatient vs. outpatient), not whether to treat.
HOST RISK FACTORS FOR BACTERIAL INFECTION
2A. Malignancy-Related Immunodeficiency
- Neutropenia (most critical): risk inversely proportional to ANC; severe risk at ANC <100
- Rate and duration of neutropenia are as important as the nadir value
- Hematologic malignancies (AML, ALL, MDS): bone marrow infiltration/failure → leukopenia
- CLL: functional hypogammaglobulinemia → encapsulated bacteria (S. pneumoniae, H. influenzae)
- Multiple myeloma: restricted immunoglobulin repertoire — biphasic pattern: early S. pneumoniae/H. influenzae; late S. aureus/GNR during neutropenia
- Solid tumors: obstructive infections (postobstructive PNA, cholangitis, pyelonephritis), necrosis, surgical complications
- Asplenia / functional asplenia (post-GVHD, splenic irradiation): overwhelming encapsulated bacteria (S. pneumoniae #1, H. influenzae, N. meningitidis)
2B. Treatment-Related Risk Factors
| FACTOR | MECHANISM / IMPLICATION |
|---|---|
| Cytotoxic chemotherapy | Bone marrow suppression → neutropenia; GI mucositis → mucosal barrier disruption → translocation of oral flora (viridans strep, gram-negative rods, Candida) |
| High-dose corticosteroids (>20mg/day prednisone) | Impairs neutrophil, monocyte, lymphocyte function; risk of PJP, TB, fungal, bacterial — often masks fever and inflammatory signs |
| Allogeneic HCT | Prolonged neutropenia + GVHD therapy → highest risk. Encapsulated bacteria risk persists due to functional asplenia from chronic GVHD |
| Alemtuzumab / purine analogs | Profound and prolonged lymphopenia; opportunistic infections (PJP, CMV, fungi) |
| CAR T-cell therapy | CRS, lymphodepletion → neutropenia; similar prophylaxis to autologous HCT |
| Vascular access devices (VADs) | Central-line associated BSI (CLABSI): coag-negative Staph, S. aureus, gram-negative rods, Candida |
| GI mucositis (grade 3-4) | Highest risk for viridans strep bacteremia; compromised mucosal barrier for GNR and Candida translocation |
| Malnutrition / poor performance status | Impaired immunity, delayed wound healing, poor response to therapy |
💎 PEARL: In CLL, early infections = pneumococcal/H. influenzae; late/heavily pretreated = gram-negative and opportunistic (PJP). Up to 90% of fludarabine-refractory CLL patients experience serious infectious complications requiring hospitalization.
⚠ Corticosteroids and many immunotherapies can blunt fever and inflammatory signs — the clinical threshold to treat must be lower in patients on high-dose steroids.
COMMON BACTERIAL PATHOGENS IN ONCOLOGY
| CATEGORY | ORGANISM | CLINICAL PEARLS / CONTEXT |
| Gram-Positive | Coagulase-negative Staphylococci (CoNS) | Most common CLABSI; often contaminant vs. true infection — compare peripheral + central cultures for DTP; may require catheter removal |
| Staphylococcus aureus (MSSA/MRSA) | Requires 4 weeks of therapy after first negative blood culture; ID consult mandatory; catheter removal highly recommended | |
| Viridans group Streptococci | GI mucositis association; penicillin resistance increasingly common; consider vancomycin in severe mucositis patients | |
| Enterococcus faecalis/faecium (VRE) | VRE: rising resistance; linezolid or daptomycin (higher doses 8–12 mg/kg/d); tedizolid (new option per NCCN 2026) | |
| Streptococcus pneumoniae | Asplenic patients/CLL/myeloma; may present as overwhelming pneumococcal sepsis; vaccinate prior to immunosuppression | |
| Gram-Negative | Escherichia coli | Most common GNR bacteremia; ESBL-producing strains require carbapenem; urinary tract source common |
| Klebsiella pneumoniae | ESBL and KPC (carbapenem-resistant) increasingly common; KPC requires novel agents (ceftazidime-avibactam) | |
| Pseudomonas aeruginosa | Most feared GNR in neutropenia; rapidly lethal; ALL empiric regimens must have antipseudomonal activity; catheter removal favored for BSI | |
| Enterobacter species | AmpC beta-lactamase — can emerge on 3rd gen cephalosporins; prefer carbapenems for serious infections | |
| Stenotrophomonas maltophilia | Intrinsically resistant to carbapenems; TMP/SMX first-line; catheter removal favored | |
| Anaerobes | Bacteroides spp., Clostridium spp. | Abdominal/perirectal infections; typhlitis; ensure anaerobic coverage for abdominal pain, perirectal pain, necrotizing lesions (updated NCCN 2026) |
| Intracellular / Atypical | Legionella, Mycoplasma, Chlamydia | Lung infiltrates (FEV-9); add azithromycin/fluoroquinolone/doxycycline for atypical coverage; urine Legionella antigen |
| CDI | Clostridioides difficile | Diarrhea in oncology patients: always test if not on laxatives/tube feeds; can be confused with chemo-induced diarrhea, neutropenic enterocolitis, GI GVHD |
🔴 PHARMACIST WATCHOUT: Never use ceftazidime as sole agent for FN — poor Gram-positive activity and breakthrough streptococcal infections have been reported (Category 2B only per NCCN).
🔴 PHARMACIST WATCHOUT: Stenotrophomonas is intrinsically RESISTANT to carbapenems — if you escalate to a carbapenem in a non-responding patient, you may miss this pathogen. Always check culture sensitivities.
💎 PEARL: Initial infections in FN are primarily bacterial. Yeast, mold, and viruses are common causes of SUBSEQUENT infections. After 4–7 days of persistent fever on antibiotics → consider empiric antifungal.
INITIAL EVALUATION — FEV-1 (NCCN v1.2026)
4A. Clinical Assessment
- Complete history & physical including: major comorbid illness, type & time since last chemotherapy, history of prior significant infections, recent antibiotic therapy/prophylaxis, medications, use of devices
- Epidemiologically relevant exposures
- Laboratory/radiology: CBC with differential, comprehensive metabolic panel
- Chest X-ray and urinalysis: ONLY if patient has symptoms (not routine)
4B. Microbiologic Evaluation
| TEST | NCCN SPECIFICATION |
|---|---|
| Blood cultures | ≥2 sets (1 set = 2 bottles). Preferred: 1 peripheral + 1 from catheter (to detect CLABSI via differential time-to-positivity [DTP] ≥2 hours) |
| Urine culture | ONLY if patient has urinary symptoms or abnormal urinalysis. Exercise caution interpreting results if urinary catheter is present |
| C. difficile assay | For diarrhea. NOTE: do NOT test if patient is on laxatives/stool softeners/tube feeds (may cause false-positive scenario by contamination) |
| Skin aspirate/biopsy | For skin lesions or drainage — send for bacterial, fungal, and mycobacterial cultures + histopathology |
| Viral diagnostics (PCR/DFA) | For vesicular/ulcerated skin or mucosal lesions; throat/nasopharyngeal swab for respiratory virus symptoms (especially during outbreaks) |
🔴 PHARMACIST WATCHOUT: Do NOT delay antibiotics while waiting for culture results. Blood cultures should be obtained BEFORE antibiotics start if possible, but do not delay empiric therapy >1 hour.
💎 PEARL: Differential time-to-positivity (DTP): If central line culture turns positive ≥2 hours before peripheral culture → suggests CLABSI. This guides catheter removal decisions.
⚠ For patients recently in the community or newly admitted, additional testing for enteric pathogens can be considered.
RISK STRATIFICATION — FEV-2 (NCCN v1.2026)
5A. Low-Risk Criteria (ALL must be present — none of the high-risk factors)
- Outpatient status at time of fever development
- No associated acute comorbid illness independently indicating inpatient care
- Anticipated SHORT duration of severe neutropenia (ANC ≤100 cells/mcL for <7 days)
- Good performance status (ECOG 0–1)
- No hepatic insufficiency
- No renal insufficiency
- MASCC Risk-Index Score ≥21 OR CISNE score <3
5B. High-Risk Criteria (ANY ONE of the following = high risk)
- MASCC Risk-Index Score <21 OR CISNE score ≥3
- Inpatient at time of fever development
- Significant medical comorbidity or clinically unstable
- Allogeneic HCT
- Anticipated PROLONGED severe neutropenia: ANC ≤100 cells/mcL AND ≥7 days
- Hepatic insufficiency (AST/ALT ≥5× ULN)
- Renal insufficiency (CrCl <30 mL/min)
- Uncontrolled/progressive cancer*
- Pneumonia or other complex infections at clinical presentation
- Certain immune and/or targeted treatments (see INF-A)
- Mucositis grade 3–4
* Uncontrolled/progressive cancer = leukemia not in CR, OR other cancers with progression after >2 lines of chemo
5C. MASCC Risk-Index Score (Adults Only — NOT for Pediatrics)
| CHARACTERISTIC | WEIGHT (points) |
|---|---|
| Burden of illness: No/Mild symptoms | 5 |
| Burden of illness: Moderate symptoms | 3 |
| No hypotension (SBP >90 mmHg) | 5 |
| No COPD | 4 |
| Solid tumor OR hematologic malignancy with NO prior fungal infection | 4 |
| No dehydration requiring parenteral fluids | 3 |
| Outpatient status at onset of febrile episode | 3 |
| Age <60 years | 2 |
| TOTAL: LOW RISK = ≥21 points / HIGH RISK = <21 points | Max 26 pts |
5D. CISNE Score (Clinical Index of Stable Febrile Neutropenia)
| CHARACTERISTIC | POINTS |
|---|---|
| ECOG Performance Status ≥2 | 2 |
| Stress-induced hyperglycemia | 2 |
| COPD | 1 |
| Chronic cardiovascular disease | 1 |
| Mucositis NCI Grade ≥2 | 1 |
| Monocytes <200/μL | 1 |
| TOTAL: LOW RISK = <3 / HIGH RISK = ≥3 | Max 8 pts |
💎 PEARL: MASCC ≥21 identifies LOW-RISK patients safe for outpatient oral therapy. CISNE <3 is an alternative. Use BOTH for complementary risk assessment.
🔴 PHARMACIST WATCHOUT: MASCC is validated for ADULTS ONLY. No generalized risk-stratified management exists for pediatric FN patients.
⚠ Even low-risk patients require close follow-up (daily × first 72 hours), return precautions, 24-hour caregiver at home, phone access, and distance within ~1 hour of medical center.
ANTIMICROBIAL PROPHYLAXIS — INF-1 (NCCN v1.2026)
Neutropenia definition for prophylaxis: ANC ≤500 cells/mcL OR ≤1000 cells/mcL with predicted decline to ≤500/mcL within 48 hours
| RISK LEVEL | DISEASE / THERAPY EXAMPLES | ANTIMICROBIAL PROPHYLAXIS |
|---|---|---|
| LOW | Standard chemo regimens for most solid tumors; anticipated neutropenia <7 days | Bacterial: NONE Fungal: NONE Viral: NONE unless prior HSV episode |
| INTERMEDIATE | Autologous HCT; Lymphoma; Multiple myeloma; CLL; Purine analogs (fludarabine, clofarabine, nelarabine, cladribine); CAR T-cell therapy; Anticipated neutropenia 7–10 days | Bacterial: Consider fluoroquinolone prophylaxis during neutropenia* Fungal: Consider during neutropenia/mucositis (INF-2); consider PJP prophylaxis (INF-6) Viral: During neutropenia and longer depending on risk (INF-3, 4, 5) |
| HIGH | Allogeneic HCT (including cord blood); Acute leukemia (induction, consolidation/ maintenance); Alemtuzumab; Moderate-severe GVHD; Anticipated neutropenia >10 days | Bacterial: Consider fluoroquinolone prophylaxis during neutropenia* Fungal: Consider during neutropenia (INF-2); consider PJP prophylaxis (INF-6) Viral: During neutropenia and longer depending on risk (INF-3, 4, 5) Note: Length of prophylaxis depends on immune reconstitution |
* Fluoroquinolone prophylaxis alternatives per NCCN:
- First-line: Fluoroquinolone (ciprofloxacin or levofloxacin) during neutropenia period
- For fluoroquinolone-intolerant patients: TMP/SMX OR oral third-generation cephalosporin (Category 2B)
- CRITICAL: If patient received prior fluoroquinolone prophylaxis → do NOT use oral fluoroquinolone for treatment (Category 1)
6A. PJP Prophylaxis — INF-6 (High Infection Risk)
| HIGH RISK POPULATION | DURATION | AGENT |
|---|---|---|
| Allogeneic HCT (Category 1) | ≥6 months while on IST | TMP/SMX preferred (Cat 1) |
| Cellular immunotherapies: CAR T-cell, TCR, TIL therapy | ≥3–6 months after transplant | If TMP/SMX intolerant: Atovaquone, Dapsone, or Pentamidine (aerosolized or IV) |
| ALL (Category 1) | Throughout anti-leukemic therapy | |
| Alemtuzumab therapy | ≥2 months + CD4 >200 cells/mcL | |
| Corticosteroids ≥20mg prednisone daily for ≥4 weeks; Temozolomide ± radiation | Through active treatment |
🔴 PHARMACIST WATCHOUT: TMP/SMX for PJP prophylaxis: DOUBLE STRENGTH (DS) 3×/week OR single-strength daily. Treatment dosing for active PJP = 8–15 mg/kg/day of TMP component IV in divided doses q6–8h.
🔴 PHARMACIST WATCHOUT: Dapsone: Check G6PD level BEFORE initiating — risk of hemolytic anemia in G6PD-deficient patients.
💎 PEARL: TMP/SMX, when appropriately dosed, ALSO has activity against Nocardia, Toxoplasma, and Listeria — useful ‘bonus’ coverage in allogeneic HCT patients.
🔴 PHARMACIST WATCHOUT: Fluoroquinolone FDA Warnings: Tendinopathy/tendon rupture, QTc prolongation, peripheral neuropathy, CNS effects — discuss risks when recommending for prophylaxis. These warnings MUST be discussed with patients.
LOW-RISK OUTPATIENT THERAPY — FEV-3 & FEV-4 (NCCN v1.2026)
7A. Social Criteria Required for Home Therapy (ALL must be met)
- Patient consents to home care
- 24-hour home caregiver available
- Telephone access
- Access to emergency facilities
- Adequate home environment
- Distance within approximately 1 hour of medical center / treating physician’s office
7B. Criteria for ORAL Antibiotic Therapy
- No nausea/vomiting
- Able to tolerate oral medications
- NOT on prior fluoroquinolone prophylaxis
7C. Treatment Options (FEV-4)
| REGIMEN | NOTES | EVIDENCE |
|---|---|---|
| Ciprofloxacin 500–750 mg PO q12h + Amoxicillin/clavulanate 875/125 mg PO q12h | Preferred 1st-line oral combination; amoxicillin-clavulanate adds Gram-positive coverage. Use CLINDAMYCIN in place of amox-clav for PCN allergy | Category 1 |
| Moxifloxacin 400 mg PO daily | Sufficient Gram-positive and atypical activity; INSUFFICIENT for Pseudomonas aeruginosa — only for low-risk patients who do not require Pseudomonas coverage | Category 1 |
| Levofloxacin 500–750 mg PO daily | Good Gram-positive and Gram-negative; no anaerobic activity; less evidence than ciprofloxacin + amox/clav combination | Acceptable |
| IV antibiotics at home (daily long-acting IV ± oral) | For patients unable to tolerate oral therapy; administered at home or in office | Alternative |
7D. Follow-Up Requirements for Outpatient Management
- Patient must be monitored DAILY
- Daily assessment for first 72 hours: assess response, toxicity, adherence
- If responding: telephone follow-up daily thereafter
- Specific reasons to RETURN TO CLINIC (any positive culture, new signs/symptoms, persistent/recurrent fever at 3–5 days, inability to continue oral regimen, scheduled IV antibiotics)
- Consider 2–12 hour observation period (Category 2B) after first dose to confirm low-risk status and organize discharge plans
🔴 PHARMACIST WATCHOUT: Moxifloxacin has INSUFFICIENT activity against Pseudomonas aeruginosa — only use for low-risk patients where P. aeruginosa coverage is not expected to be needed.
💎 PEARL: The Category 1 recommendation for ciprofloxacin + amoxicillin-clavulanate is one of the most heavily validated outpatient FN regimens. The combination covers Gram-negative (including Pseudomonas) + Gram-positive organisms synergistically.
HIGH-RISK INPATIENT EMPIRIC THERAPY — FEV-5 (NCCN v1.2026)
Initial antibiotic selection should be based on:
- Infection risk assessment (FEV-2)
- Broad-spectrum coverage INCLUDING antipseudomonal activity
- Colonization with or prior infection with MDROs
- Site of infection
- Local antibiotic susceptibility patterns (ASP/antibiogram)
- Organ dysfunction / drug allergy
- Previous antibiotic therapy / prophylaxis received
| AGENT | DOSE | EVIDENCE | KEY COMMENTS |
|---|---|---|---|
| Cefepime | 2 g IV q8h | Category 1 | Broad Gram(+)/Gram(-); NOT anaerobes/Enterococcus; CNS OK with susceptible organisms; ⚠ neurotoxicity with renal dysfunction |
| Piperacillin/ Tazobactam | 4.5 g IV q6h OR extended infusion 3.375–4.5 g q8h over 4h | Category 1 | Broad including anaerobes; use for suspected intra-abdominal; NOT for meningitis; standard or extended infusion |
| Meropenem | 1–2 g IV q8h OR 500 mg IV q6h | Category 1 | Preferred over imipenem for CNS infections; ESBL and Enterobacter coverage; reserve for MDROs |
| Imipenem/ Cilastatin | 500 mg IV q6h | Category 1 | NOT preferred for CNS infections; may lower seizure threshold (renal dysfunction, CNS malignancy/infection) |
| Ceftazidime | 2 g IV q8h | Category 2B | Poor Gram(+) activity; breakthrough streptococcal infections reported — add Gram(+) agent if used. Resistance among certain GNRs limits utility |
8A. When to Add Vancomycin (or Gram-Positive Coverage) — NOT Routine
Vancomycin should NOT be added routinely. Add ONLY when specific risk factors/sites are present:
| INDICATION | COMMENT |
|---|---|
| Cellulitis / skin and soft tissue infection | Consider for MRSA coverage; add Gram(+) agent (vancomycin) |
| Vascular Access Device (VAD) infection | Vancomycin initially; add if site not responding after 48h of empiric therapy; tunnel/port pocket infection → remove catheter + add vancomycin |
| Sinus/nasal + periorbital cellulitis | Consider adding MRSA and anaerobic coverage if periorbital cellulitis noted (updated NCCN 2026) |
| Lung infiltrates with MRSA suspected | Vancomycin OR linezolid if MRSA suspected (FEV-9) |
| Disseminated papules | Consider vancomycin or other Gram(+) coverage (FEV-A) |
| CNS infection | Empiric therapy MUST cover Pseudomonas aeruginosa AND Listeria; meropenem preferred over imipenem |
8B. Severe Beta-Lactam Allergy Management
- For severe beta-lactam allergy (anaphylaxis): Consider VANCOMYCIN + AZTREONAM while further evaluation is carried out with ID/allergy consultation (NCCN FEV-5 footnote)
- Aztreonam: monobactam with Gram-negative coverage including Pseudomonas — can be used safely in most penicillin-allergic patients
- ID/allergy consultation STRONGLY recommended for severe allergy patients — formal allergy evaluation and desensitization may allow optimal therapy
8C. Combination Therapy Considerations
- IV monotherapy is TYPICALLY used for uncomplicated FN with anti-Pseudomonal beta-lactam
- IV combination therapy (eg, add aminoglycoside) may be considered where antimicrobial resistance is suspected or in hemodynamically unstable patients
- Aminoglycosides (amikacin, gentamicin, tobramycin): used as part of combination in seriously ill/hemodynamically unstable patients; primarily Gram-negative activity
- Extended/continuous infusion of beta-lactams: emerging data support use for highly resistant infections (see Discussion)
🔴 PHARMACIST WATCHOUT: Cefepime neurotoxicity: encephalopathy, myoclonus, non-convulsive status epilepticus — especially in patients with renal dysfunction. Monitor mental status changes closely.
🔴 PHARMACIST WATCHOUT: Carbapenems (imipenem > meropenem) can LOWER SEIZURE THRESHOLD in patients with CNS malignancies, CNS infection, or renal insufficiency. Prefer meropenem for any CNS-involved infection.
🔴 PHARMACIST WATCHOUT: Ertapenem does NOT have anti-Pseudomonal activity — do NOT use ertapenem for febrile neutropenia.
💎 PEARL: For ESBL-producing organisms and serious Enterobacter infections: carbapenems are the drugs of choice. Imipenem/meropenem are specifically noted as preferred for ESBL and Enterobacter in NCCN FEV-A.
SITE-SPECIFIC EVALUATION & THERAPY — FEV-6, 7, 8, 9 (NCCN v1.2026)
⚠ ALL patients with febrile neutropenia should receive broad-spectrum antibiotics (FEV-5) PLUS site-specific modifications below.
| SITE | PRESENTATION | EVALUATION | TREATMENT MODIFICATION |
| Mouth / Mucosal Membrane | Necrotizing ulceration | HSV/VZV diagnostics; culture & Gram stains; fungal; biopsy suspicious lesions | Ensure ADEQUATE ANAEROBIC COVERAGE (updated NCCN 2026); consider anti-HSV/VZV therapy; consider systemic antifungal |
| Thrush | Clinical diagnosis ± fungal culture | Antifungal: Fluconazole first-line; voriconazole/posaconazole/echinocandin if refractory | |
| Vesicular lesions | HSV/VZV diagnostics | Anti-HSV therapy (Category 1): acyclovir/valacyclovir/famciclovir | |
| Esophagus | Retrosternal burning; dysphagia; odynophagia | HSV and CMV diagnostics; fungal culture of suspicious oral lesions; consider endoscopy if no response | Initial therapy guided by clinical findings (eg, thrush → antifungal; perioral HSV → antiviral). Consider endoscopy + histopathology for viral and fungal pathogens |
| Sinus / Nasal | Sinus tenderness; periorbital cellulitis; nasal ulceration; unilateral eye tearing | High-resolution CT sinus/orbit MRI; ENT + ophthalmologic urgent evaluation; culture/stains/biopsy | Consider adding MRSA and anaerobic coverage if periorbital cellulitis (updated NCCN 2026); add lipid amphotericin B if high-risk with suspicious CT/MRI (aspergillosis/mucormycosis) |
| Abdominal Pain | Abdominal pain, tenderness, distension | Abdominal CT (preferred) or ultrasound; LFTs (ALP, AST, ALT, bili), amylase, lipase | Consider adding ANAEROBIC coverage (updated NCCN 2026); early surgical/GI/IR consultation; consider typhlitis (neutropenic enterocolitis) |
| Perirectal Pain | Perirectal pain, fluctuance, swelling | Perirectal inspection; consider abdominal/pelvic CT or MRI | ENSURE ADEQUATE ANAEROBIC COVERAGE (updated NCCN 2026); consider local care; surgical consultation if abscess |
| Diarrhea | Loose stools (not from laxatives/tube feeds) | C. difficile testing; consider colonoscopy for colitis; test for viral/bacterial/parasitic pathogens as clinically indicated | C. difficile positive → FEV-10; CDI negative → treat underlying cause. Colonoscopy may be needed to evaluate GI GVHD vs. mucositis vs. infection |
| Urinary Tract Symptoms | Dysuria, frequency, urgency | Urine culture | No additional antibiotic therapy until specific pathogen identified from culture |
| Cellulitis / SSTI | Erythema, warmth, swelling, fluctuance | Consider aspirate or biopsy for culture | Add Gram(+)-active agents; consider MRSA coverage (vancomycin) |
| Vascular Access Device (VAD) | Entry/site inflammation OR tunnel/port pocket infection, septic phlebitis | Swab drainage for culture; blood cultures from VAD AND peripheral (DTP) | Entry inflammation: vancomycin initially OR add after 48h if not responding. Tunnel/port pocket/septic phlebitis: REMOVE CATHETER + culture + vancomycin (NCCN) |
| CNS Symptoms | Headache, AMS, focal neuro deficit, meningismus | MRI (preferred) or CT; LP (if possible); ID + neurology consult | Empiric meningitis therapy MUST cover Pseudomonas aeruginosa AND Listeria; for encephalitis → add high-dose acyclovir with hydration + monitor renal function |
| Lung Infiltrates | New infiltrate, cough, dyspnea, hypoxia | CT scan; blood/sputum cultures; Aspergillus galactomannan (blood + BAL); consider BAL; Legionella/pneumococcal urine antigen; PJP PCR; mycobacterial PCR | Add atypical coverage (azithromycin, doxycycline, or fluoroquinolone); consider mold-active antifungal; TMP/SMX if PJP possible; vancomycin/linezolid if MRSA suspected; antiviral if influenza season |
🔴 PHARMACIST WATCHOUT: For lung infiltrates, microbial cell-free DNA testing (plasma) can be considered by center preference — experience is variable. Do NOT replace standard bronchoscopy/BAL in complex cases.
🔴 PHARMACIST WATCHOUT: Antiviral susceptibility of influenza strains is VARIABLE and cannot be predicted from prior outbreaks. Always check current susceptibility patterns and CDC/IDSA guidelines for current-season influenza therapy.
💎 PEARL: In CNS infection, Listeria monocytogenes coverage requires ampicillin or TMP/SMX — neither carbapenems nor cephalosporins reliably cover Listeria. Meropenem covers Pseudomonas, but you need to add ampicillin or TMP/SMX for Listeria coverage.
CLOSTRIDIOIDES DIFFICILE INFECTION (CDI) — FEV-10 (NCCN v1.2026)
NCCN FEV-10 cross-references: IDSA CDI 2021 Focused Update (Clin Infect Dis 2021)
| CDI SEVERITY / SETTING | TREATMENT | NOTES |
| Initial CDI (non-severe) | Fidaxomicin 200 mg PO BID × 10 days OR Vancomycin 125 mg PO QID × 10 days | Discontinue unnecessary antibiotics. Optimize to avoid high/moderate-risk antibiotics; limit PPIs if possible |
| Ongoing/Worsening CDI | Discontinue unnecessary antibiotics Fidaxomicin 200 mg PO BID × 10 days OR Vancomycin 125 mg PO QID × 10 days | Consider switching to fidaxomicin if initially on vancomycin; FDA-approved live biotherapeutics (AVOID in neutropenic patients) |
| Relapse / Recurrent CDI | Fidaxomicin (if not previously used) OR Vancomycin or fidaxomicin TAPER OR With appropriate consultation: FDA-approved live biotherapeutics (avoid in neutropenia) | Bezlotoxumab may be added (with consultation) for recurrence prevention; live biotherapeutics: avoid if on/likely to be on broad-spectrum antibiotics soon (NCCN 2026) |
| Fulminant CDI | Oral vancomycin 500 mg QID (or via NG tube) PLUS IV metronidazole 500 mg TID If ileus present: consider vancomycin via rectal instillation | IV metronidazole added to oral vancomycin for FULMINANT ONLY — not standard severity. Consider early colectomy consult for deteriorating cases |
🔴 PHARMACIST WATCHOUT: Live biotherapeutics (FDA-approved fecal microbiota products) must be AVOIDED in patients with neutropenia AND in patients who are on or likely to be on broad-spectrum antibiotics in the near term (NCCN 2026 update).
🔴 PHARMACIST WATCHOUT: For CDI, test ONLY if patient is not on laxatives, stool softeners, or tube feeds — these may cause diarrhea that mimics CDI and confound testing.
💎 PEARL: Fidaxomicin is preferred over vancomycin for CDI in oncology patients — lower recurrence rate, narrower spectrum preserving gut microbiome. IDSA 2021 and NCCN both support fidaxomicin as preferred agent.
💎 PEARL: If patient has recurrent CDI while on active cancer treatment (which requires antibiotics), the key clinical challenge is maintaining oncologic therapy while managing CDI — requires close ID + GI collaboration.
⚠ For ongoing or worsening CDI: If initially treated with vancomycin → consider switching to fidaxomicin per NCCN FEV-10 updated guidance.
DAILY MONITORING & FOLLOW-UP THERAPY — FEV-11 & FEV-12 (NCCN v1.2026)
11A. Daily Monitoring Decision Framework (FEV-11)
| CLINICAL STATUS | ANC STATUS | ACTION |
| Clinically stable/improving; fever decreasing (DOCUMENTED INFECTION) | Any | Targeted treatment of documented infection; reassess empiric broad-spectrum therapy; de-escalate as possible |
| Fever resolved, UNKNOWN origin | ANC ≥500 cells/mcL | Discontinue antibiotics |
| Fever resolved, UNKNOWN origin | ANC <500 cells/mcL | OPTIONS: (1) Discontinue therapy; (2) De-escalate to fluoroquinolone after ≥48h afebrile; (3) Continue current regimen ONLY if significant concern for ongoing infection |
| PERSISTENTLY FEBRILE, otherwise clinically stable | Persistent neutropenia | Broaden coverage based on clinical/micro data; consider imaging/further testing; consider G-CSF/GM-CSF (Cat 2B); ID consult; consider empiric antifungal if fever ≥4 days on antibiotics |
| CLINICALLY WORSENING | Any | Urgent: broaden antibiotic coverage; imaging/microbiologic testing; consider G-CSF (Cat 2B); ID consult; empiric mold-active antifungal for fever ≥4–7 days |
11B. Suggested Duration of Therapy for Documented Infections (FEV-12)
These are general guidelines for uncomplicated disease. Duration may be modified based on neutrophil recovery, defervescence rapidity, site of infection, pathogen, and underlying illness.
| INFECTION TYPE | NCCN DURATION GUIDANCE |
| Skin/soft tissue infection | 5–14 days |
| Gram-negative bacteremia | 7–14 days |
| Gram-positive bacteremia | 7–14 days |
| S. aureus bacteremia (MSSA or MRSA) | Typically MINIMUM 4 WEEKS after first negative blood culture (some centers may use shorter with ID consult). ID CONSULT STRONGLY RECOMMENDED (associated with decreased mortality) |
| Bacterial sinusitis | 5–14 days |
| Bacterial pneumonia | 5–14 days |
| Candida bloodstream infection | ≥2 WEEKS after FIRST NEGATIVE blood culture. ID consult recommended. |
| Candida non-BSI (mold/yeast) | Minimum of 2 weeks; mold: minimum 12 weeks |
11C. Catheter Removal Indications (FEV-12)
- HIGHLY RECOMMENDED for: S. aureus, P. aeruginosa, Candida/other yeasts, Corynebacterium jeikeium, Acinetobacter spp., nontuberculous mycobacteria, molds, VRE, Stenotrophomonas maltophilia, other MDROs
- Mandatory: Tunnel infection, port pocket infection, septic phlebitis
- Strongly recommended: Blood cultures persistently positive (updated NCCN 2026: ‘catheter removal highly recommended if blood cultures persistently positive’)
💎 PEARL: The threshold for adding empiric mold-active antifungal is fever persisting ≥4 days on antibiotics. In HIGH-RISK patients (neutropenia >10 days, allogeneic HCT, high-dose corticosteroids), NCCN recommends adding empiric antifungal by day 4 UNLESS patient is already receiving mold-directed prophylaxis.
🔴 PHARMACIST WATCHOUT: S. aureus bacteremia REQUIRES ID consult — ID consult is independently associated with decreased mortality. Minimum 4 weeks of therapy. Obtain echocardiogram to rule out endocarditis.
🔴 PHARMACIST WATCHOUT: De-escalation from empiric broad-spectrum therapy is ESSENTIAL — prolonged broad-spectrum use drives resistance and C. difficile infection. Always attempt de-escalation when culture data allows.
ANTIBACTERIAL AGENTS — DOSING, SPECTRUM, MONITORING (FEV-A, NCCN v1.2026)
Standard adult dosing for normal renal function. Adjust for renal/hepatic insufficiency and obesity per institutional guidelines.
12A. Gram-Positive Active Agents (FEV-A 1 of 3)
These agents should NOT be used as monotherapy for FN — add only if high suspicion of resistant Gram-positive infection or specific risk factors.
| AGENT | DOSE | SPECTRUM | KEY COMMENTS / MONITORING |
| Vancomycin | 15 mg/kg IV q12h; loading dose may be considered | Gram(+) organisms EXCEPT VRE and some rare Gram(+) | IV formulation only. TDM (AUC/MIC target 400–600 per ASHP/IDSA/SIDP). Not routine for FN — add only for specific indications. Nephrotoxic (especially with other nephrotoxins); infusion-related (Red Man Syndrome — slow rate, premedicate) |
| Daptomycin | 6–10 mg/kg/day IV; higher doses (8–12 mg/kg) for certain BSIs (eg, enterococci) | Gram(+); in vitro VRE activity | Weekly CPK monitoring for rhabdomyolysis. NOT indicated for pneumonia (inactivated by pulmonary surfactant). ID consult strongly recommended for dosing in BSI/endocarditis |
| Linezolid | 600 mg PO/IV q12h | Gram(+) including VRE and MRSA | Hematologic toxicity (thrombocytopenia 0.3–10%, esp. >2 weeks); serotonin syndrome with SSRIs/SNRIs; peripheral/optic neuropathy with long-term use; Treatment option for VRE and MRSA (NCCN 2026) |
| Tedizolid | 200 mg PO/IV DAILY | Gram(+) including VRE and MRSA | NEW NCCN 2026: Treatment option for VRE and MRSA. Less hematologic toxicity vs. linezolid with prolonged use. Once-daily dosing advantage. Less serotonergic risk than linezolid. |
12B. Anti-Pseudomonal Agents (FEV-A 2 of 3)
⚠ No agents in the anti-Pseudomonal group are active against MRSA or VRE — always layer Gram(+) coverage separately when needed.
| AGENT | DOSE | SPECTRUM | KEY COMMENTS / MONITORING |
| Cefepime | 2 g IV q8h | Broad Gram(+)/Gram(-); NOT anaerobes, NOT Enterococcus | Category 1 for FN. Use for suspected/proven CNS infection with susceptible organism. Mental status changes especially with renal dysfunction (neurotoxicity). Renal dose adjustment required. |
| Ceftazidime | 2 g IV q8h | Poor Gram(+) activity; NOT anaerobes, NOT Enterococcus | Category 2B for FN. Breakthrough streptococcal infections reported — add Gram(+) agent if used. Increasing GNR resistance. Use for CNS infections with susceptible organism. |
| Imipenem/ Cilastatin | 500 mg IV q6h | Broad Gram(+), Gram(-), anaerobes; preferred for ESBL/serious Enterobacter | Category 1. NOT preferred for CNS (seizures). Seizure risk: CNS malignancy/infection, renal insufficiency. Meropenem preferred for CNS. Ertapenem is NOT anti-Pseudomonal. |
| Meropenem | 1–2 g IV q8h OR 500 mg IV q6h | Broad Gram(+), Gram(-), anaerobes; ESBL; Enterobacter | Category 1. PREFERRED over imipenem for CNS. Lower seizure risk. Extended infusion (3h) may optimize PK/PD for resistant organisms. |
| Piperacillin/ Tazobactam | 4.5 g IV q6h (severe/FN) OR 3.375 g IV q6h (mild-moderate); extended infusion: 3.375–4.5 g q8h over 4h | Broad Gram(+), Gram(-), anaerobes | Category 1. Use for suspected intra-abdominal source. NOT for meningitis. Extended infusion may improve efficacy against borderline-susceptible organisms (pharmacodynamic optimization). |
12C. Other Antibacterial Agents (FEV-A 3 of 3)
| AGENT | DOSE | SPECTRUM | KEY COMMENTS |
| Aminoglycosides (Amikacin/ Gentamicin/ Tobramycin) | Extended-interval: Gentamicin/Tobramycin 5–7 mg/kg q24h; Amikacin 15–20 mg/kg q24h | Primarily Gram-negative organisms | Used in combination for seriously ill/hemodynamically unstable. Nephrotoxic + ototoxic — TDM mandatory. Avoid in renal insufficiency unless no alternative. |
| Ciprofloxacin | 500–750 mg PO q12h OR 400 mg IV q8–12h | Gram(-) and atypical; LESS Gram(+) than levofloxacin; NO anaerobic activity | Avoid if prior fluoroquinolone prophylaxis. Increasing Gram-negative resistance. FDA Black Box: tendinopathy, peripheral neuropathy, QTc. QTc monitoring. Propylaxis in intermediate/high risk neutropenia. |
| Levofloxacin | 500–750 mg PO or IV daily | Gram(-), improved Gram(+) vs. cipro, atypical organisms; NO anaerobes | Same Black Box warnings as ciprofloxacin. Prophylaxis option for intermediate/high risk. Limited as empiric therapy for FN. QTc monitoring. |
| Moxifloxacin | 400 mg PO or IV daily | Gram(-), Gram(+), anaerobes; INSUFFICIENT vs. Pseudomonas | Category 1 for outpatient low-risk FN. NOT for Pseudomonas. Same FDA Black Box warnings. QTc monitoring important — highest QTc effect among fluoroquinolones. |
| Metronidazole | 500 mg PO (preferred) q8–12h | Anaerobic organisms primarily | Add for anaerobic coverage in abdominal/perirectal infections. Peripheral neuropathy with prolonged use (>4 weeks). PO preferred over IV when possible. |
| TMP/SMX | Prophylaxis: SS daily or DS 3×/week Treatment: 8–15 mg/kg/day (TMP component) IV in divided doses q6–8h | P. jirovecii; Toxoplasma gondii; Nocardia; Listeria; Stenotrophomonas | Monitor: renal insufficiency, myelosuppression, hepatotoxicity, hyperkalemia. Interaction with methotrexate (folate antagonism — increased toxicity). G6PD not required for TMP/SMX. |
12D. Novel Agents for MDROs (ID Consult Required — FEV-A footnote)
These agents have variable spectrum/activity and should ONLY be used with expert consultation:
- Ceftolozane-tazobactam: MDR Pseudomonas aeruginosa
- Ceftazidime-avibactam: KPC-producing Klebsiella, OXA-48 Enterobacterales, MDR Pseudomonas
- Meropenem-vaborbactam: KPC-producing CRE
- Imipenem-cilastatin-relebactam: carbapenem-resistant Enterobacterales, MDR Pseudomonas
- Cefiderocol: broad MDR Gram-negative including NDM, metallo-beta-lactamase producers, Acinetobacter
🔴 PHARMACIST WATCHOUT: Vancomycin dosing: Use AUC/MIC-guided monitoring (AUC 400–600 mg·h/L per 2020 ASHP/IDSA/SIDP guidelines) rather than trough-only monitoring. Continuous infusion strategies are emerging but institution-dependent.
🔴 PHARMACIST WATCHOUT: Daptomycin CANNOT be used for pneumonia — it is inactivated by pulmonary surfactant. Use linezolid or tedizolid instead for MRSA pneumonia.
💎 PEARL: Extended infusion of piperacillin-tazobactam (eg, 4.5g over 4h q8h) optimizes the %T>MIC pharmacodynamic parameter — particularly beneficial for borderline-susceptible organisms and confirmed at many institutions.
HEMATOPOIETIC GROWTH FACTORS (G-CSF) — NCCN v3.2026
13A. Primary Prophylaxis — Risk-Based Approach
| FN RISK | RISK CATEGORY | RECOMMENDATION |
| HIGH (>20%) | Regimen FN risk >20% | G-CSFs: Category 1 — administer prophylactic G-CSF with every cycle |
| INTERMEDIATE (10–20%) | Regimen FN risk 10–20% | Evaluate patient risk factors (MGF-2). If ≥1 risk factor present: Consider G-CSF. If no risk factors: Observe. |
| LOW (<10%) | Regimen FN risk <10% | G-CSFs NOT routinely recommended. May consider for patients with ≥2 patient-related risk factors based on clinical judgment. |
13B. Patient Risk Factors Warranting G-CSF Consideration (MGF-2)
- Prior chemotherapy or radiation therapy
- Persistent neutropenia
- Bone marrow involvement by tumor
- Recent surgery and/or open wounds
- Liver dysfunction (bilirubin >2.0 mg/dL)
- Renal dysfunction (CrCl <50 mL/min)
- Age >65 years receiving full chemotherapy dose intensity
- Poor performance status or HIV with low CD4 count (additional NCCN footnote factors)
13C. Therapeutic G-CSF Use in Active FN (MGF-4)
| SITUATION | ACTION |
| Already received prophylactic pegfilgrastim/eflapegrastim/efbemalenograstim | No additional G-CSF (pharmacokinetic data show high levels during neutropenia; additional G-CSF likely not beneficial — HOWEVER, for prolonged neutropenia, additional G-CSF may be considered) |
| On daily filgrastim or tbo-filgrastim | CONTINUE G-CSFs |
| No prior G-CSF — LOW infection-associated complication risk | No therapeutic MGFs |
| No prior G-CSF — HIGH infection-associated complication risk* | Consider therapeutic MGFs: Filgrastim 5 mcg/kg SQ/IV daily until post-nadir ANC recovery to normal/near-normal levels |
* High infection-associated complication risk factors (MGF-4): sepsis syndrome, age >65, ANC <100/mcL, neutropenia expected >10 days, pneumonia/documented infection, invasive fungal infection, hospitalization at time of fever, prior FN episode.
13D. G-CSF Agents and Dosing
| AGENT | PROPHYLACTIC DOSE | THERAPEUTIC DOSE | ADMIN NOTES |
| Filgrastim (Neupogen) and biosimilars (Zarxio, Nivestym) | 5 mcg/kg SQ/IV daily, start 24–72h after chemo | 5 mcg/kg SQ/IV daily until ANC recovery | Continue until ANC recovery; can be given therapeutic |
| Pegfilgrastim (Neulasta) and biosimilars | 6 mg SQ once per cycle, 24–72h after chemo; DO NOT give 14 days before to 24h after chemo | Studied for prophylaxis only — NOT for therapeutic use | Single injection per cycle; longer half-life; on-body injector available |
| Eflapegrastim-xnst (Rolontis) | 13.2 mg SQ once per cycle, 24h after chemo | Prophylaxis ONLY | Once per cycle; not for therapeutic use |
| Sargramostim/GM-CSF (Leukine) | 250 mcg/m²/day IV or SQ | 250 mcg/m²/day (clinical trials dose) | Can be used therapeutically; more side effects than G-CSF |
🔴 PHARMACIST WATCHOUT: Pegfilgrastim and eflapegrastim: DO NOT administer within 24h before or after cytotoxic chemotherapy. Risk of severe bone marrow suppression from G-CSF-stimulated progenitor proliferation at time of chemo.
🔴 PHARMACIST WATCHOUT: In patients with ADCs (antibody-drug conjugates), the half-life is significantly longer — optimal timing of G-CSF has NOT been systematically determined. Use institutional guidance.
🔴 PHARMACIST WATCHOUT: G-CSFs should NOT be withheld for neutropenia/cytopenia associated with bispecific T-cell engagers and monoclonal antibodies — administer regardless of timing during the cycle (NCCN 2026 update).
💎 PEARL: G-CSF in dose-dense regimens (eg, dose-dense AC, CHOP-14): G-CSF support is REQUIRED to maintain dose intensity and schedule — without it, dose delays and reductions will occur, compromising curative intent.
💎 PEARL: G-CSF use (Category 2B) can be added therapeutically in the FEV-11 algorithm for clinically worsening patients — mention this at rounds when patients have prolonged neutropenia and are not recovering.
⚠ Trilaciclib (CDK4/6 inhibitor): FDA-approved to decrease incidence of chemo-induced myelosuppression when administered BEFORE platinum/etoposide ± ICI for ES-SCLC or topotecan for SCLC. A prophylactic G-CSF may still be administered after cycle 1.
KEY CLINICAL TRIALS — QUICK REFERENCE
| TRIAL / STUDY | POPULATION | INTERVENTION | COMPARATOR | KEY RESULTS |
| MASCC Risk Index (Klastersky, JCO 2000) | Adults with FN (multicenter, n=756) | MASCC score ≥21 = low risk | Clinical outcomes | MASCC ≥21: 71% sensitivity, 68% specificity for low-risk. Positive predictive value 91% for no serious complications |
| CISNE Validation (Carmona-Bayonas, JCO 2015) | Stable FN patients (FINITE study, n=1133) | CISNE score <3 = low risk | MASCC score | CISNE score better identified low-risk ‘stable’ FN patients than MASCC; complementary tools, not replacements |
| Oral vs IV empiric FN (Kern, NEJM 1999) | Low-risk FN adults (n=203) | Ciprofloxacin + amoxicillin-clavulanate PO | IV ceftazidime | Success rate 99% (oral) vs 97% (IV) — oral non-inferior; established oral empiric therapy for low-risk FN |
| Pegfilgrastim Prophylaxis (Holmes, JCO 2002) | Breast cancer chemo (n=928) | Pegfilgrastim 6 mg SQ × 1/cycle | Filgrastim daily × 11 days | Non-inferior efficacy; simpler single-dose administration; established pegfilgrastim as standard G-CSF prophylaxis |
| Fidaxomicin vs Vancomycin CDI (Cornely, Lancet Infect Dis 2012) | Non-severe/severe CDI (n=535) | Fidaxomicin 200 mg BID × 10d | Vancomycin 125 mg QID × 10d | Similar clinical cure; significantly lower recurrence with fidaxomicin (15% vs 25%). Established fidaxomicin as preferred for CDI recurrence prevention |
| G-CSF Primary Prophylaxis Meta-Analysis (Kuderer, JCO 2007) | Solid tumor/lymphoma on chemo (17 RCTs, n=3493) | G-CSF prophylaxis | Placebo/no G-CSF | G-CSF reduced FN incidence by 46%; reduced infection-related mortality; established primary prophylaxis benefit for high-risk regimens |
| Letermovir CMV Prophylaxis (Marty, NEJM 2017) | CMV-seropositive allogeneic HCT recipients (n=570) | Letermovir 480 mg PO/IV daily through day 100 | Placebo | 37.5% vs 60.6% clinically significant CMV infection at week 24. FDA-approved; NCCN 2026: consider through day 100–200 post-HCT |
| Extended Infusion Pip-Tazo (Dulhunty, JAMA 2015) | ICU bacteremia/sepsis (n=432) | Piperacillin/tazobactam extended infusion over 4h | Standard 30-min infusion | No significant difference in 90-day survival in this ICU trial; PK/PD rationale remains strong for MDR organisms; institutional variation exists |
MASTER CLINICAL PEARLS — HEM/ONC PHARMACIST
15A. Febrile Neutropenia Pharmacotherapy Pearls
- 1. Febrile neutropenia is an ONCOLOGIC EMERGENCY — empiric IV antibiotics within 1 hour of triage. Time to antibiotics is associated with mortality outcomes.
- 2. Risk stratification (MASCC ≥21 or CISNE <3) identifies low-risk patients for oral outpatient therapy. Both scores are complementary, validated in adults only.
- 3. ALL empiric IV regimens for inpatient FN MUST include antipseudomonal activity. Monotherapy with a Category 1 agent (cefepime, pip/tazo, meropenem, or imipenem) is standard.
- 4. Vancomycin is NOT routine — add only for specific indications: SSTI, VAD infection, MRSA-suspected pneumonia, sinus/nasal with periorbital cellulitis, disseminated lesions, hemodynamic instability from suspected Gram(+) source.
- 5. Ceftazidime is Category 2B for FN only — poor Gram(+) coverage and increasing GNR resistance limit its utility. Always add Gram(+) agent if used.
- 6. Do NOT use ertapenem for FN — no anti-Pseudomonal activity.
- 7. De-escalation is critical — prolonged broad-spectrum antibiotics drive resistance and CDI. De-escalate as soon as culture data allows and patient is clinically stable.
- 8. If fever persists ≥4 days on antibiotics → consider empiric mold-active antifungal. In high-risk patients (neutropenia >10 days, allogeneic HCT, high-dose steroids): recommend starting by day 4.
- 9. S. aureus bacteremia = ID consult mandatory + echocardiogram to rule out endocarditis + minimum 4 weeks of therapy.
- 10. For CDI in oncology: fidaxomicin > vancomycin (lower recurrence). AVOID live biotherapeutics in neutropenic patients.
15B. Pharmacist Watchouts for Multidisciplinary Rounds & Tumor Board
- 1. Antibiogram review: Always check local resistance patterns before recommending empiric therapy — institutional susceptibility data trump guidelines for specific pathogens.
- 2. Fluoroquinolone prophylaxis → oral fluoroquinolone treatment: NEVER use oral fluoroquinolone as empiric treatment in a patient who received prior fluoroquinolone prophylaxis — resistance is expected.
- 3. Renal dosing: Cefepime, vancomycin, aminoglycosides, TMP/SMX, fluoroquinolones ALL require dose adjustments in renal insufficiency. Check CrCl before every order.
- 4. Cefepime + renal impairment: Risk of neurotoxicity (encephalopathy, myoclonus) increases significantly. Dose-reduce and monitor mental status closely.
- 5. Vancomycin TDM: AUC/MIC monitoring (target 400–600 mg·h/L) is now preferred over trough-only monitoring (per 2020 ASHP/IDSA/SIDP guidelines). Check your institution’s policy.
- 6. Azole antifungals (posaconazole, voriconazole, itraconazole): Strong CYP3A4 inhibitors — significantly increase vincristine, cyclophosphamide metabolites, and many targeted agents. Always check drug interactions when initiating antifungal prophylaxis.
- 7. Posaconazole IV formulation requires normal renal function (sulfobutylether betacyclodextrin vehicle) — use oral DR tablet for patients with CrCl <50 mL/min.
- 8. Venetoclax + posaconazole: NCCN INF-A explicitly flags that venetoclax requires dose REDUCTION with P-gp inhibitors or strong/moderate CYP3A inhibitors including posaconazole.
- 9. G-CSF timing: Never give pegfilgrastim/eflapegrastim within 24h before or after cytotoxic chemo. Filgrastim: start 24–72h after last chemo dose.
- 10. Daptomycin for pneumonia: NEVER use — inactivated by pulmonary surfactant. Use vancomycin, linezolid, or tedizolid for MRSA pneumonia.
- 11. Tedizolid (NCCN 2026 update): New MRSA and VRE treatment option; once-daily dosing; less hematologic toxicity than linezolid — useful in prolonged courses needed in oncology patients.
- 12. Methotrexate + TMP/SMX: Both folate antagonists — concurrent use substantially increases methotrexate toxicity. Document carefully and counsel team.
- 13. CDI testing pitfall: False-positive CDI tests in patients on laxatives/stool softeners/tube feeds. Confirm with clinical picture before treating.
- 14. DTP for CLABSI: Instruct nurses to draw peripheral blood culture SIMULTANEOUSLY with central line cultures — differential time-to-positivity (≥2h) diagnoses CLABSI and guides catheter removal.
- 15. Listeria in CNS infection: Neither carbapenems nor cephalosporins reliably cover Listeria — must add ampicillin or TMP/SMX for CNS coverage.
15C. Patient Counseling Points
- 1. Fever is a medical emergency: Instruct patients to check temperature and call the oncology line/go to ER IMMEDIATELY for oral temperature ≥38.3°C or ≥38.0°C for 1 hour.
- 2. Outpatient FN (low-risk): Take oral antibiotics EXACTLY as prescribed, have caregiver present 24/7, return immediately for new symptoms, worsening, inability to take medications, or fever not improving by day 3–5.
- 3. Fluoroquinolone warnings: Explain risk of tendon rupture (stop and call if tendon pain), peripheral neuropathy (numbness/tingling), and QT prolongation (avoid OTC meds that prolong QT without checking).
- 4. Prophylactic antibiotics: Explain purpose (infection prevention during chemotherapy), expected duration (during neutropenic period), and that they do NOT treat active infection if fever develops — seek evaluation immediately.
- 5. G-CSF injection technique: Teach site rotation (abdomen, thigh, upper arm), timing relative to chemo, common side effects (bone pain — manage with NSAIDs if not contraindicated, loratadine can help with bone pain from filgrastim), and when to contact clinic.
- 6. Infection prevention: Hand hygiene, avoiding sick contacts, safe food handling (immunocompromised diet), dental hygiene, avoiding sources of Aspergillus (soil, plants, construction sites during high-risk periods).
QUICK REFERENCE ALGORITHMS & CHECKLISTS
16A. Febrile Neutropenia Algorithm (NCCN FEV-1 → FEV-5)
STEP 1 — IDENTIFY: Is this Febrile Neutropenia?
Fever: Single temp ≥38.3°C oral OR ≥38.0°C oral over 1 hour
Neutropenia: ANC ≤500/mcL OR ≤1000/mcL with predicted decline to ≤500/mcL within 48h
Both criteria present? → FEBRILE NEUTROPENIA — proceed immediately
STEP 2 — EVALUATE: History, Physical, Labs, Cultures (FEV-1)
H&P: Last chemo date/type, prior infections, prior antibiotics, medications, VAD in place
Labs: CBC with diff, CMP, consider CXR if respiratory symptoms, UA if urinary symptoms
Blood cultures: ≥2 sets — 1 peripheral + 1 from catheter (preferred)
Site-specific diagnostics: C. diff assay (if diarrhea), skin aspirate/biopsy, viral PCR/DFA for lesions
STEP 3 — STRATIFY: Low Risk vs. High Risk (FEV-2)
Low risk: Outpatient at fever onset; ECOG 0-1; no severe neutropenia >7d; no comorbidities; MASCC ≥21 or CISNE <3 → Outpatient oral therapy possible
High risk: ANY of — inpatient at fever; allogeneic HCT; neutropenia ≤100 cells/mcL ≥7d; hepatic insufficiency; CrCl <30; pneumonia/complex infection; mucositis grade 3-4 → INPATIENT
STEP 4A — LOW RISK TREATMENT (FEV-3/4)
Confirm social criteria (caregiver, phone, transportation, consents)
Oral therapy: Ciprofloxacin 500–750 mg PO q12h + amoxicillin-clavulanate 875/125 mg PO q12h (Cat 1) OR Moxifloxacin 400 mg PO daily (Cat 1, no Pseudomonas needed) OR Levofloxacin 500–750 mg PO daily
NOT on prior fluoroquinolone prophylaxis (required for oral FQ regimen)
Daily monitoring × 72h; return precautions; telephone follow-up
STEP 4B — HIGH RISK TREATMENT (FEV-5)
IV monotherapy with antipseudomonal agent (Category 1): Cefepime 2g IV q8h OR Pip/Tazo 4.5g IV q6h OR Meropenem 1-2g IV q8h OR Imipenem 500mg IV q6h
Add vancomycin ONLY for: SSTI, VAD infection, periorbital cellulitis, MRSA-suspected PNA, disseminated lesions
Adjust for prior MDROs, site of infection, local susceptibilities
Severe PCN allergy: Vancomycin + aztreonam + ID/allergy consultation
16B. Antibiotic Stewardship Checklist — Pharmacist Role
| PHARMACIST STEWARDSHIP CHECKLIST | |
| [ ] | Confirm indication: Is this true FN? (verify temperature definition + ANC threshold) |
| [ ] | Cultures before antibiotics (if feasible and safe without delaying therapy >1h) |
| [ ] | Appropriate empiric regimen selected based on: risk stratification, site of infection, prior MDRO history, allergy status, local antibiograms |
| [ ] | Renal function verified — dose adjust ALL renally-cleared antibiotics |
| [ ] | Vancomycin TDM ordered (AUC/MIC) if vancomycin initiated |
| [ ] | Daily review of culture results for de-escalation opportunity |
| [ ] | Duration reviewed: Does documented infection have a specific NCCN-recommended duration? |
| [ ] | Catheter removal discussed for appropriate pathogens (S. aureus, Pseudomonas, Candida, VRE, MDROs) |
| [ ] | CDI assessment: Any diarrhea? Any unnecessary antibiotics to discontinue/optimize? |
| [ ] | Antifungal needed? Fever >=4 days on antibiotics in high-risk patient? |
| [ ] | G-CSF status: Primary/secondary prophylaxis indicated? Therapeutic G-CSF for high-risk worsening patient? |
| [ ] | Drug interactions: Any azole antifungals started that may interact with chemotherapy agents? |
ABBREVIATIONS
| ABBR | MEANING | ABBR | MEANING |
| ANC | Absolute Neutrophil Count | MDR | Multidrug-Resistant |
| AUC | Area Under the Curve | MDRO | Multidrug-Resistant Organism |
| BAL | Bronchoalveolar Lavage | MSSA | Methicillin-Sensitive S. aureus |
| BSI | Bloodstream Infection | MRSA | Methicillin-Resistant S. aureus |
| CAR | Chimeric Antigen Receptor | NCCN | National Comprehensive Cancer Network |
| CDI | Clostridioides difficile Infection | PJP | Pneumocystis jirovecii Pneumonia |
| CISNE | Clinical Index of Stable FN | PPE | Palmar-Plantar Erythrodysesthesia |
| CLABSI | Central Line-Associated BSI | SSTI | Skin and Soft Tissue Infection |
| CrCl | Creatinine Clearance | TDM | Therapeutic Drug Monitoring |
| DTP | Differential Time to Positivity | TMP/SMX | Trimethoprim/Sulfamethoxazole |
| ESBL | Extended-Spectrum Beta-Lactamase | ULN | Upper Limit of Normal |
| FN | Febrile Neutropenia | VAD | Vascular Access Device |
| GNR | Gram-Negative Rod | VRE | Vancomycin-Resistant Enterococcus |
| GVHD | Graft-Versus-Host Disease | VZV | Varicella Zoster Virus |
| HCT | Hematopoietic Cell Transplant | G-CSF | Granulocyte Colony-Stimulating Factor |
| MASCC | Multinational Assoc Supportive Care in Cancer | IST | Immunosuppressive Therapy |
Key References
- 1. NCCN Clinical Practice Guidelines in Oncology — Prevention and Treatment of Cancer-Related Infections, Version 1.2026 (March 11, 2026)
- 2. NCCN Clinical Practice Guidelines in Oncology — Hematopoietic Growth Factors, Version 3.2026 (December 5, 2025)
- 3. Klastersky J, et al. The Multinational Association for Supportive Care in Cancer risk index. J Clin Oncol 2000;18:3038-3051. [MASCC Score]
- 4. Carmona-Bayonas A, et al. Prediction of serious complications in patients with stable febrile neutropenia (CISNE validation). J Clin Oncol 2015;33:465-471.
- 5. McDonald LC, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update (IDSA/SHEA). Clin Infect Dis 2018;66:987-994.
- 6. Rybak MJ, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline. ASHP/IDSA/SIDP, 2020.
- 7. Kuderer NM, et al. Effect of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality. J Clin Oncol 2007;25:3158-3167.
- 8. Marty FM, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med 2017;377:2433-2444.
- 9. Cornely OA, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-289.
Prepared for Hem/Onc Pharmacotherapy Reference | NCCN Guidelines v1.2026 | For educational use only